News
-
Glenmark Pharmaceuticals has revealed that the FDA issued a complete response letter to the company’s NDA for Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray. The agency accepted the NDA for Ryaltris in August 2018 with a… Read more . . .
-
According to Syqe Medical, the company has received regulatory approval from the Israeli Ministry of Health to launch its metered-dose cannabis inhaler in Israel for the treatment of pain. The inhaler, which was previously available only… Read more . . .
-
The Japanese Ministry of Health, Labour and Welfare has approved AstraZeneca’s Bevespi Aerosphere glycopyrronium/formoterol fumarate MDI for the treatment of COPD, the company said. Bevespi Aerosphere has been approved for the treatment of COPD in the US since… Read more . . .
-
Boehringer Inhgelheim has opened a new €120 million Respimat manufacturing facility in Sant Cugat del Vallés, Spain, near Barcelona, the company said. The 17,000 sq m plant is expected to produce 25 million units per… Read more . . .
-
Theravance Biopharma and Mylan have expanded their 2015 development and commercialization agreement for nebulized revefenacin (formerly TD-4208) to include China, Hong Kong, Macau, and Taiwan. The 2015 agreement included all markets except for China and… Read more . . .
-
Upsher-Smith Laboratories has acquired the US rights to Tosymra sumatriptan nasal spray from Dr. Reddy’s Laboratories, the companies have announced. The FDA approved Dr. Reddy’s subsidiary Promius Pharma’s NDA for Tosymra in January 2019. The… Read more . . .
-
Members of the OINDP community are remembering inhalation expert Ola Nerbrink, who passed away on June 1, 2019. He was the CEO of Respiron Consulting, which he founded in 2009, and VP of Business Development… Read more . . .
-
Proveris Scientific announced that Stephen McDonald has joined the company’s European team, which is based in the UK. McDonald, who has previously worked with Proveris to provide customer support as an independent contractor, will work… Read more . . .
-
Inhaled drug developer Savara has announced that the Phase 3 IMPALA study of Molgradex inhaled formulation recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP) failed to meet its primary… Read more . . .
-
During the 2019 annual meeting of the American Diabetes Association (ADA), Dance Biopharm presented data from the Phase 2 Samba 04 clinical trial of Dance 501 inhaled insulin for the treatment of Type 2 diabetes… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland